Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 14Leukemia, Myeloid, Acute 7Neoplasms 3Neoplasm Metastasis 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neuroblastoma 2Liver Neoplasms 2Hepatoblastoma 2Fibrolamellar hepatocellular carcinoma 2Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Sarcoma, Myeloid 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors 1Melanoma 1Gastrointestinal Stromal Tumors 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cytarabine 4venetoclax 2Mitoxantrone 2Daunorubicin 2Cladribine 2thymoglobulin 1quizartinib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1blinatumomab 1Transplantation 1Thiotepa 1Tacrolimus 1Sorafenib 1Sirolimus 1Rituximab 1Razoxane 1Mesna 1Melphalan 1Leyk 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Dexrazoxane 1Cyclophosphamide 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Sorafenib × 1 year × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡